Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 12INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 78Biopsy 69Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 14Disulfides 14X-Rays 13Radiation 13Doxorubicin 12venetoclax 11Radiotherapy 11Gemcitabine 11durvalumab 9cabozantinib 8aldesleukin 8Prednisone 8atezolizumab 7Cytarabine 7olaparib 6lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NIH × Protons × Clear all
NCT04671667 2026-06-05

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
188 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡